Artelo Biosciences, Inc. (ARTL) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Artelo Biosciences, Inc. (ARTL) Healthcare & Pipeline Overview

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company specializing in endocannabinoid system modulation for conditions like cancer-related anorexia and PTSD. Their pipeline, featuring synthetic G protein-coupled receptor agonists and cannabidiol cocrystals, positions them in the competitive biotechnology sector with a focus on unmet medical needs.

What Is the Investment Thesis for ARTL?

Artelo Biosciences, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on modulating the endocannabinoid system offers potential for novel therapies targeting conditions with significant unmet needs. Key value drivers include the successful completion of clinical trials for ART27.13, ART12.11, and ART26.12, leading to potential regulatory approvals and commercialization. Upcoming catalysts include the progression of ART27.13 through its Phase 1b/2a clinical trial for cancer-related anorexia and the advancement of ART12.11 and ART26.12 into later-stage clinical development. The collaboration with Trinity College Dublin could also yield valuable insights and accelerate the development of ART27.13 for cancer cachexia. However, potential risks include clinical trial failures, regulatory hurdles, competition from other companies developing similar therapies, and the need for additional funding to support ongoing research and development activities. The company's small market capitalization of $2.18M reflects its early stage and the inherent uncertainties associated with biotechnology investments.

Based on FMP financials and quantitative analysis

ARTL Key Highlights

Artelo Biosciences is a clinical-stage biopharmaceutical company focused on modulating the endocannabinoid system.

• The company's lead product candidate, ART27.13, is in Phase 1b/2a clinical trial for anorexia associated with cancer.
• Artelo is also developing ART12.11 for inflammatory bowel disease and PTSD, and ART26.12 for prostate and breast cancer and PTSD.
• The company has a research collaboration with Trinity College Dublin to investigate ART27.13 for cancer cachexia.
• Artelo Biosciences has a small market capitalization of $2.18M, reflecting its early stage and growth potential.

Who Are ARTL's Competitors?

ARTL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ARTL's Key Strengths?

Focus on the endocannabinoid system, a promising therapeutic target.

• Diverse product pipeline addressing multiple indications.
• Research collaboration with Trinity College Dublin.
• Experienced management team.

What Are ARTL's Weaknesses?

Limited financial resources.

• Small number of employees.
• Early-stage clinical development.
• Dependence on successful clinical trial outcomes.

What Could Drive ARTL Stock Higher?

Completion of Phase 1b/2a clinical trial for ART27.13 in cancer-related anorexia.

• Advancement of ART12.11 into later-stage clinical development for IBD and PTSD.
• Progress of ART26.12 in preclinical and clinical studies for prostate and breast cancer and PTSD.
• Results from research collaboration with Trinity College Dublin on ART27.13 for cancer cachexia.

What Are the Key Risks for ARTL?

Financial-distress signal — its Altman Z-Score of -19.48 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for ART27.13, ART12.11, or ART26.12.
• Regulatory delays or rejection of product candidates.
• Competition from other biotechnology and pharmaceutical companies.
• Need for additional funding to support research and development activities.
• Patent challenges or loss of intellectual property protection.

What Are the Growth Opportunities for ARTL?

• Advancement of ART27.13 for Cancer-Related Anorexia: ART27.13, a synthetic G protein-coupled receptor agonist, is currently in Phase 1b/2a clinical trials for treating anorexia associated with cancer. Successful completion of these trials and subsequent regulatory approval could provide a significant growth opportunity for Artelo. The market for anorexia treatments is substantial, with a growing need for effective therapies to improve the quality of life for cancer patients. The company's collaboration with Trinity College Dublin to investigate ART27.13 for cancer cachexia could further expand its potential applications.
• Development of ART12.11 for Inflammatory Bowel Disease and PTSD: ART12.11, a synthetic cannabidiol cocrystal, is being developed for the treatment of inflammatory bowel disease (IBD) and post-traumatic stress disorder (PTSD). Both IBD and PTSD represent significant market opportunities, with a large patient population and a growing demand for effective treatments. Successful development and commercialization of ART12.11 could generate substantial revenue for Artelo. The company's focus on a synthetic cannabidiol cocrystal may offer advantages over traditional cannabinoid-based therapies.
• Expansion of ART26.12 for Prostate and Breast Cancer: ART26.12, a fatty acid binding protein 5 inhibitor, is being explored as a potential treatment for prostate and breast cancer, as well as for PTSD. Prostate and breast cancer are two of the most prevalent cancers worldwide, representing a multi-billion dollar market opportunity. Successful development and commercialization of ART26.12 could provide a significant growth driver for Artelo. The company's focus on a fatty acid binding protein 5 inhibitor offers a novel approach to cancer treatment.
• Strategic Partnerships and Collaborations: Artelo can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. These partnerships could provide access to additional funding, expertise, and resources, enabling Artelo to expand its research and development efforts and reach a wider patient population. Collaborations could also help Artelo navigate the complex regulatory landscape and secure market access for its therapies.
• Expansion into New Therapeutic Areas: While Artelo's current pipeline focuses on cancer-related anorexia, IBD, PTSD, and prostate and breast cancer, the company could explore opportunities to expand into new therapeutic areas where modulation of the endocannabinoid system may offer potential benefits. This could include conditions such as chronic pain, neurodegenerative diseases, and autoimmune disorders. Expanding into new therapeutic areas would diversify Artelo's product portfolio and reduce its reliance on any single indication.

What Are ARTL's Competitive Advantages?

• Proprietary drug candidates targeting the endocannabinoid system.
• Patent protection for its product pipeline.
• Clinical data supporting the safety and efficacy of its therapies.
• Research collaborations with leading academic institutions.

What Does ARTL Do?

Artelo Biosciences, Inc., founded in 2011 and formerly known as Reactive Medical, Inc. until its name change in April 2017, is a clinical-stage biopharmaceutical company headquartered in Solana Beach, California. The company is dedicated to developing and commercializing treatments that modulate the endocannabinoid system, a crucial regulatory system in the human body. Artelo's approach involves creating innovative therapies for a range of conditions, including cancer-related anorexia, inflammatory bowel disease, post-traumatic stress disorder (PTSD), prostate cancer, and breast cancer. Their product pipeline features several promising candidates. ART27.13, a synthetic G protein-coupled receptor agonist, is currently in a Phase 1b/2a clinical trial for treating anorexia associated with cancer. ART12.11, a synthetic cannabidiol cocrystal, is being developed for the treatment of inflammatory bowel disease and PTSD. ART26.12, a fatty acid binding protein 5 inhibitor, is being explored as a potential treatment for prostate and breast cancer, as well as for PTSD. Artelo Biosciences also has a research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia, a wasting syndrome associated with cancer. Artelo's focus on the endocannabinoid system distinguishes it within the biotechnology industry. By targeting this system, Artelo aims to address unmet medical needs in various therapeutic areas, potentially offering new treatment options for patients with debilitating conditions. The company's clinical-stage pipeline and research collaborations reflect its commitment to advancing innovative therapies.

What Products and Services Does ARTL Offer?

• Develops and commercializes treatments to modulate the endocannabinoid system.
• Focuses on therapies for conditions like anorexia associated with cancer, inflammatory bowel disease, and PTSD.
• Develops synthetic G protein-coupled receptor agonists.
• Creates synthetic cannabidiol cocrystals.
• Develops fatty acid binding protein 5 inhibitors.
• Conducts clinical trials to evaluate the safety and efficacy of its product candidates.

How Does ARTL Make Money?

• Develops pharmaceutical products targeting the endocannabinoid system.
• Conducts research and development to identify and validate potential drug candidates.
• Out-licenses or partners with larger pharmaceutical companies for commercialization.
• Generates revenue through licensing agreements, milestone payments, and royalties.

What Industry Does ARTL Operate In?

Artelo Biosciences operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The industry is driven by innovation, with companies constantly seeking to develop new treatments for unmet medical needs. Artelo's focus on modulating the endocannabinoid system places it within a niche area of the biotechnology sector, targeting conditions such as cancer-related anorexia, inflammatory bowel disease, and PTSD. The company faces competition from other biotechnology and pharmaceutical companies developing therapies for these conditions, as well as from companies developing cannabinoid-based treatments.

Who Are ARTL's Key Customers?

• Pharmaceutical companies seeking to license or acquire novel drug candidates.
• Patients suffering from conditions treatable by endocannabinoid system modulation.
• Healthcare providers prescribing Artelo's therapies.
• Research institutions collaborating with Artelo on drug development.

Artelo Biosciences, Inc. (ARTL) Valuation Context

Valued at $2.18M, ARTL is classified as a micro-cap stock. Relative to its peer group, ARTL's quantitative score of 29/100 is below the peer average of 73/100.

ARTL Revenue & Earnings Trend

In Q2 FY2026, ARTL generated $0 in top-line revenue. The company recorded a net loss of $2.4M, with diluted EPS of $-8.05. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ARTL averaged $-17.97 in diluted EPS.

Company Profile

Artelo Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Solana Beach, US. The company is led by CEO Gregory D. Gorgas. ARTL has traded publicly since 2019.

Artelo Biosciences, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -19.48 places it in the distress zone, a signal of elevated financial risk.

Artelo Biosciences, Inc. has missed Wall Street's EPS estimate in 7 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 191.0% below estimates on average.

Over the past six months, Artelo Biosciences, Inc. insiders filed 6 SEC Form 4 transactions — 0 sales and 6 purchases. On net that is roughly 816 shares acquired (about $938) — insiders putting money in tends to read as conviction.

ARTL Financials

ARTL Latest News

ARTL Analyst Consensus

ARTL MoonshotScore

What Investors Ask About Artelo Biosciences, Inc. (ARTL) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources